{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-007580","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.043143+00:00","generated_at":"2026-06-17T18:36:42.763896+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin reports FY 2022 net loss of $29.0M; cash $43.1M, runway into Q3 2024","bullets":["Net loss $29.0M for 2022 vs $6.7M in 2021; R&D expense $19.0M (up $4.6M), G&A $11.5M.","Cash and equivalents $43.1M as of Dec 31, 2022; sufficient to fund ops into Q3 2024.","Annamycin Phase 1/2 trial in AML approved in Italy; first subjects dosed.","FDA granted Fast Track Designation for WP1122 in Glioblastoma Multiforme.","European Phase 1 Annamycin trial reported 80% overall response rate in final cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-007580","json":"https://secwatch.observer/filing/0001437749-23-007580.json","markdown":"https://secwatch.observer/filing/0001437749-23-007580.md","text":"https://secwatch.observer/filing/0001437749-23-007580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/0001437749-23-007580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/mbrx20230321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:36:42.763896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cf0783f604bcb46675afb1123571d09e9d10d05","claim":"Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2022 results: net income $29.0 million.","evidence_excerpt":"The net loss for the year ended December 31, 2022 was $29.0 million, which included non-cash gains of $1.3 million on warrants in 2022 as compared to $6.7 million in the prior year and approximately $2.3 million of stock-based compensation expense in 2022 as compared to $2.4 million in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923007580/0001437749-23-007580-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Net income","value":"$29.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}